Bladder cancer readout sees Nektar shares hit

Nektar has had a mixed few months as data fed through for its lead cancer drug NKTR-214, but new data in bladder cancer should help steady the ship, although a drop in ORR has hit the biotech's shares.

The biotech is due to report updated results from its PIVOT-02 trial of NKTR-214 in combination with partner Bristol-Myers Squibb’s Opdivo at the ASCO Genitourinary Cancers Symposium later this week.